More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says
More than 20,000 people have started taking Eli Lilly's newly approved weight loss pill, Foundayo, in its first few weeks on the market, according to CEO Dave Ricks. The drug, which is the second oral GLP-1 medication available after Novo Nordisk's version, is seeing strong organic demand with over 1,000 new users daily. Lilly reported strong first-quarter sales for its other GLP-1 drugs, Mounjaro and Zepbound, as it aims to maintain its leading share in the U.S. obesity and diabetes drug market.
Opening excerpt (first ~120 words) tap to expand
More than 20,000 people have started taking Eli Lilly's GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. The FDA approved Lilly's once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk's Wegovy pill. Investors have been closely tracking weekly prescriptions for clues on how the launch is going. More than 1,000 people are starting Foundayo a day, Ricks said in an exclusive interview with CNBC. He said it'll take time to build the brand since it's a new drug that doctors and patients don't know.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Business.
Discussion
0 commentsMore from CNBC — Business
